Annovis Bio completes data cleaning for Phase II/III study of buntanetap in Alzheimer's patients, with topline efficacy data expected in April.

Annovis Bio, a clinical-stage drug platform firm, has completed data cleaning for its Phase II/III study of buntanetap in mild to moderate Alzheimer's patients. The company is now organizing and statistically evaluating the data, with topline efficacy data expected in April. Buntanetap targets neurodegeneration by inhibiting multiple neurotoxic proteins linked to Alzheimer's disease.

Articles

Market Screener

MENAFN

TMCnet

Street Insider

Business Insider

Street Insider

Market Screener

-- show less --

Further Reading

Related Stories